FindTrial
Sign In

To study about DSC3 protein presence in triple negative hormone status in breast cancer patients.

Evaluation of DSC-3 expression in triple negative breast cancer (TNBC) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/064982
Enrollment
50
Registered
2024-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: Not applicable: Not applicable

Sponsors

Tata Memorial Centre
Lead Sponsor
Artemis Health Research Foundation
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Histopathological diagnosis of TNBC. 2.Patients who have undergone curative surgery (BCT or MRM) for breast cancer either after initial treatment or after neoadjuvant chemotherapy. 3.Either disease free survival from the time of diagnosis of atleast 2 years and no relapse OR relapse after initial curative treatment at any timepoint. 4.Initial clinical stage 1 to 3 disease. 5.Availability of the paraffin blocks of fulfilling the above criteria.

Exclusion criteria

Exclusion criteria: 1.Non availability of tumor tissue block. 2.No available survival data.

Design outcomes

Primary

MeasureTime frame
To evaluate the immunohistochemical expression of DSC3 in tumor blocks of patients with triple negative breast cancer and determine the cutoff levels of its expression for segregating patients with and without relapse in the discovery cohortTimepoint: 12 months—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactDr Sudeep Gupta
sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026